EP2536815B1 - Verwendung von liposomen zur behandlung von textilien - Google Patents

Verwendung von liposomen zur behandlung von textilien Download PDF

Info

Publication number
EP2536815B1
EP2536815B1 EP11704413.1A EP11704413A EP2536815B1 EP 2536815 B1 EP2536815 B1 EP 2536815B1 EP 11704413 A EP11704413 A EP 11704413A EP 2536815 B1 EP2536815 B1 EP 2536815B1
Authority
EP
European Patent Office
Prior art keywords
agents
inci
acid
liposomes
cationic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP11704413.1A
Other languages
English (en)
French (fr)
Other versions
EP2536815A1 (de
Inventor
Alfonso FERNÁNDEZ BOTELLO
Josep-Lluís Viladot Petit
Raquel DELGADO GONZÁLEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lipotec SA
Original Assignee
Lipotec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipotec SA filed Critical Lipotec SA
Publication of EP2536815A1 publication Critical patent/EP2536815A1/de
Application granted granted Critical
Publication of EP2536815B1 publication Critical patent/EP2536815B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A61K8/553—Phospholipids, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/817—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions or derivatives of such polymers, e.g. vinylimidazol, vinylcaprolactame, allylamines (Polyquaternium 6)
    • A61K8/8182—Copolymers of vinyl-pyrrolidones. Compositions of derivatives of such polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A61Q7/02—Preparations for inhibiting or slowing hair growth
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D17/00—Detergent materials or soaps characterised by their shape or physical properties
    • C11D17/0039—Coated compositions or coated components in the compositions, (micro)capsules
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/20—Organic compounds containing oxygen
    • C11D3/22—Carbohydrates or derivatives thereof
    • C11D3/222—Natural or synthetic polysaccharides, e.g. cellulose, starch, gum, alginic acid or cyclodextrin
    • C11D3/227—Natural or synthetic polysaccharides, e.g. cellulose, starch, gum, alginic acid or cyclodextrin with nitrogen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/36—Organic compounds containing phosphorus
    • C11D3/362—Phosphates or phosphites
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/36—Organic compounds containing phosphorus
    • C11D3/364—Organic compounds containing phosphorus containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/37—Polymers
    • C11D3/3703—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • C11D3/3723—Polyamines or polyalkyleneimines
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/37—Polymers
    • C11D3/3703—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • C11D3/373—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds containing silicones
    • C11D3/3742—Nitrogen containing silicones
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/37—Polymers
    • C11D3/3746—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • C11D3/3769—(Co)polymerised monomers containing nitrogen, e.g. carbonamides, nitriles or amines
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/38—Products with no well-defined composition, e.g. natural products
    • D—TEXTILES; PAPER
    • D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
    • D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
    • D06M13/00—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment
    • D06M13/244—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment with compounds containing sulfur or phosphorus
    • D06M13/282—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment with compounds containing sulfur or phosphorus with compounds containing phosphorus
    • D06M13/292—Mono-, di- or triesters of phosphoric or phosphorous acids; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/10—General cosmetic use

Definitions

  • This invention relates to microfluidized liposomes which contain cosmetic and/or dermopharmaceutical agents wherein these liposomes are coated with a cationic polymer which conserves the positive charge necessary for an effective adsorption of the liposomes in natural or synthetic fibers.
  • the release of the liposomes and therefore the cosmetic and/or dermopharmaceutical agents which contain these liposomes is carried out through the standard methods of pressure, skin pH, friction, osmosis or heat.
  • This invention refers to liposomes with cosmetic and/or dermopharmaceutical ingredients for the care of the skin, scalp and/or hair.
  • the cationic polymers on the surface of the liposomes allow their effective linking to the fibers of the textile material.
  • the preparation of textile materials with chemical products linked to them has been extensively studied to provide textile materials with cosmetic and/or dermopharmaceutical purposes, i.e. textile materials which release cosmetic and/or dermopharmaceutical agents in contact with the skin.
  • the aforementioned cosmetic and/or dermopharmaceutical active ingredients to have a greater permanence on the textile material than at present, since the delivery systems which contain these active ingredients are separated from the textile material after a few washes.
  • Application EP 1972324 A discloses liposomes treated with a cationic polymer to form capsules (claim 1).
  • the publication refers to encapsulated liposomes (page 2, line 52), i.e., a capsule formed by the cationic polymer on the surface of the previously formed liposome (page 6, line 2, page 6, line 49, page 8, lines 9-10) wherein the capsule is substantially spherical (page 8, lines 17-18).
  • US 20080317795 A discloses a stable liposomal formulation wherein the liposomes encapsulate active biological materials for the in vivo administration to a living organism.
  • the publication describes anionically charged liposomes that form large aggregates with a cationic polymer or cationic liposomes.
  • DE 102004017996 A discloses a sol-gel microcapsule having a cationic surface charge.
  • the sol-gel microcapsule contains an active ingredient for delivery to a target substrate or site, including encapsulated actives within a liposome capsule, which are used as templates for the formation of cationically charged sol-gel microcapsules (par. [0226], Example 7).
  • WO 2008089707 A discloses "liposomes" consisting of a solid nucleus containing a textile auxiliary agent and a membrane containing a phospholipid and optionally cholesterol, a surfactant and/or a water soluble polymer of cationic type.
  • a liposome as "an artificial vesicle composed of one or more concentric phospholipid bilayers and used especially to deliver microscopic substances (as drugs or DNA) to body.
  • the disclosed textile auxiliary agent is selected from salts and dispersants (page 13, line 18 to page 14, line 3).
  • the dispersant is selected from a group including water-soluble vinyl polymers and/or co-polymers of anionic, non-ionic, and cationic types, such as the sodium salt of poly(acrylic acid), sodium salt of hydrolyzed poly(maleic anhydride), amidated and imidated poly(maleic anhydride), its co-polymers and quaternized derivatives, poly(vinyl alcohol), and its co-polymers with maleic anhydride and/or acrylic acid.
  • This invention relates to the use of microfluidized liposomes which contain cosmetic and/or dermopharmaceutical active ingredients and/or adjuvants, and which are linked to cationic polymers in the treatment of textile materials, wherein these polymers form a network over the surface of the textile material when they are brought into contact.
  • This network on the surface of the textile material enables a more effective linking of the liposomes to the textile material than in the case of the liposomes known in the prior art.
  • the invention is defined in the appended claims. Liposomes are a commonly used solution which prolongs the period of availability of an active agent.
  • the material on the wall of the liposome presents a resistance and thermal stability that are such that the liposome is not destroyed under storage conditions, but the mechanical release of the encapsulated substances is enabled under light pressure action, or thermal release at a temperature of 35 to 220°C.
  • Another possibility consists of the liposome wall becoming semi-permeable in its properties through its modification such as from pressure, friction or heat.
  • liposome relates to an approximately spherical aggregate formed by at least a double layer or bilayer of at least one phospholipid wherein the layers are very close and the apolar regions of each layer face the apolar regions of the other lipid layer, and thus the polar regions of the phospholipids form the internal and external face of the double layer or bilayer.
  • the liposomes of this invention can have just one bilayer and are structured like unilaminar liposomes, or they can have from 2 to 6 bilayers, concentric or non-concentric, of lipids, preferably from 2 to 4 concentric bilayers, and will then be organized as multilaminar liposomes like onions, or can have from 2 to 6 bilayers and be organized like unilaminar liposomes which are comprised of 1 to 5 smaller unilaminar liposomes.
  • the liposomes in this invention present a nucleus which can contain a series of hydrophilic cosmetic and/or dermopharmaceutical active ingredients, and at least a lipid bilayer which can contain hydrophobic cosmetic and/or dermopharmaceutical active ingredients.
  • the phospholipid of the liposomes of this invention is a natural or synthetic phosphoglyceride and is preferably selected from the group formed by phosphatidylserine, phosphatidylinositol, phosphatidylethanolamine, phosphatidylcholine, phosphatidic acid, phosphatidylglycerol, diphosphatidylglycerol, phosphorylcholine, cardiolipin, their fatty acid esters, hydrogenation products and mixtures thereof, such as and not restricted to natural lecithins such as that from an egg, soy or sunflower.
  • the fatty acids are found, for example and not restricted to, stearic, palmitic, oleic, myristic, lauric acid and any saturated or unsaturated fatty acids known in the prior art.
  • the phospholipids used are phosphatidylcholine, phosphatidylethanolamine and phosphatidylinositol.
  • the liposomes are mixed liposomes formed by one or more phospholipids and one or more homogeneously distributed surfactants in each of the double layers or bilayers and with the aforementioned described structures for the liposomes.
  • the surfactant of these mixed liposomes is selected from the group formed by non-ionic surfactants, amphoteric surfactants, anionic surfactants, cationic surfactants and mixtures thereof.
  • the surfactants are non-ionic surfactants and/or amphoteric surfactants, more preferably they are selected from the group formed by alkylglycosides with an alkyl group which has from 6 to 24 carbon atoms, alkylmaltosides with an alkyl group which has from 6 to 24 carbon atoms, ethoxylated alkylphenols with an alkyl group which has from 6 to 24 carbon atoms and from 5 to 30 units of ethylene oxide, alkyl phenyl polyoxyethylene ethers with an alkyl group which has from 6 to 24 carbon atoms, saturated or unsaturated fatty alcohols with an alkyl group which has 8 to 24 carbon atoms, poloxamers, polysorbates, sorbitan esters, polyethylene glycol fatty acid esters, ricin oils, fatty alcohol and polyoxyethylene ethers, fatty acid alkanolamides, amine oxides, alkyl betaines with an alkyl group which has from 6 to 24
  • the cationic polymers bound to the liposomes are natural or synthetic polymers, selected from the group as defined in claim 1. They may be formed by cationic derivatives of cellulose, such as quaternized hydroxyethylcellulose, which can be acquired under the name Polymer JR 400TM by Amerchol, cationic starches, copolymers of diallylammonium and acrylamide salts, quaternized vinylpyrrolidone/vinylimidazole polymers such as LuviquatTM (BASF), condensation products of polyglycols and amines, polyquaternium polymers and copolymers, polymers named Merquats of polyquaternium-6, polyquaternium-7; polyquaternium-16, polyquaternium-10, polyquaternium-4 copolymers, dicocoylethylhydroxyethylammonium, graft copolymers with a cellulose backbone and quaternary ammonium groups, quaternized collagen polypeptides such as lauryldi
  • the liposomes of this invention which contain cosmetic and/or dermopharmaceutical active ingredients and/or adjuvants can be applied to the natural or synthetic fibers of textile materials before or after manufacture.
  • textile materials are understood to be fabrics, non-woven fabrics, garments and medical devices. Examples of fabrics, non-woven fabrics, garments, medical devices and means for immobilization of liposomes can be found in the literature and are known in the prior art (" Impregnating Fabrics With Microcapsules", HAPPI May 1986 ; Int. J. Pharm. 2002, 242, 55-62 ; " Biofunctional Textiles and the Skin” Curr. Probl. Dermatol. 2006 v.3 ; J. Cont. Release 2004, 97, 313-320 ).
  • Preferred means for immobilizing liposomes in textile materials are carried out through application using washing agents or the use of sprays without needing to soak the textile materials.
  • this invention provides a considerable improvement on the binding of liposomes to the natural or synthetic fibers of the surface of the textile material during a prolonged period due to the network structure that the cationic polymers form on the textile material in relation to the liposomes bound to cationic monomers known in the prior art.
  • the natural and/or synthetic fibers can be wool, cotton, silk, nylon fibers, cellulose or polyester, among others.
  • the preferred woven fabrics, non-woven fabrics, garments and medical devices are bandages, gauzes, t-shirts, socks, tights, underwear, girdles, gloves, diapers, sanitary napkins, dressings, bedspreads, wipes, hydrogels, adhesive patches, non-adhesive patches, micro-electric patches and/or face masks.
  • the cosmetic and/or dermopharmaceutical active ingredients and/or adjuvants contained in the liposomes can be transferred to the skin, scalp and/or hair, after the skin, scalp and/or hair have been brought into contact with the liposome, through mechanical pressure, friction, osmosis or heat.
  • the liposomes of the invention either due to biodegradation of the linking system to the textile material or due to friction between the textile material and the body, or due to body moisture or due to the body temperature, release the cosmetic and/or dermopharmaceutical active ingredients and/or adjuvants.
  • the resulting phospholipids and the cosmetic and/or dermopharmaceutical active ingredients and/or adjuvants form a fine film on the surface of the textile materials which facilitates contact with the skin, scalp and/or hair and subsequently the transfer of the active ingredients and/or adjuvants through mechanical processes such as friction.
  • the cationic polymers bound to the liposomes modify their structure making them more flexible, which also allows the liposomes to cross or penetrate the skin, scalp and/or hair with greater ease, thus increasing the penetration of the cosmetic and/or dermopharmaceutical active ingredients and/or adjuvants.
  • the liposomes of this invention undergo micro-fluidification, which allows homogenization of the liposomes through high pressure, smaller sized liposomes are obtained which affords them greater stability and consistency in comparison with the liposomes which have not undergone micro-fluidification.
  • the cationic polymer has positive charges which electrostatically interact with the phosphate group of the phospholipids which form the lipid membrane of the liposomes. Therefore, the same cationic polymer can interact with several liposomes at once forming a framework or network of liposomes whose overall charge is positive and which are linked to the surface of the textile materials at several points.
  • this framework or network includes several liposomes within the same cationic polymeric network where the size of the cationic polymer is in the region of 600-1700 nm, in comparison with the size of the liposomes which are smaller or equal to 300 nm, in particular, smaller than 200 nm.
  • the inside of the liposomes contains cosmetic and/or dermopharmaceutical active ingredients and/or adjuvants.
  • the cosmetic and/or dermopharmaceutical active ingredients and/or adjuvants for the treatment and/or care of the skin, scalp and/or hair are selected, for example and not restricted to, the group formed by surfactants, humectants or substances which retain moisture, emollients, moisturizers, agents stimulating healing, coadjuvant healing agents, agents stimulating re-epithelialization, coadjuvant re-epithelialization agents, agents stimulating the synthesis of dermal or epidermal macromolecules, firming and/or redensifying and/or restructuring agents, cytokine growth factors, agents acting on capillary circulation and/or microcirculation, anti-glycation agents, free radical scavengers and/or anti-atmospheric pollution agents, reactive carbonyl species scavengers, 5 ⁇ -reduct
  • cosmetic and/or dermopharmaceutical agents and/or adjuvants can be synthetic or natural, such as vegetable extracts, or come from a biotechnological process or from a combination of a synthetic process and a biotechnological process. Additional examples can be found in the CTFA International Cosmetic Ingredient Dictionary & Handbook, 12th Edition (2008 ).
  • a biotechnological process is understood to be any process which produces the active ingredient, or part of it, in an organism, or in a part of it.
  • the surfactant which may be contained in the liposomes of this invention is any of the aforementioned surfactants which form the mixed liposomes.
  • the humectant or substance that retains moisture, moisturizer or emollient which can be contained in the liposomes of this invention is selected, for example and not restricted to, from the group formed by polyols and polyethers such as glycerin, ethylhexylglycerin, caprylyl glycol, pentylene glycol, butylene glycol, propylene glycol and their derivatives, triethylene glycol, polyethylene glycol, Glycereth-26, Sorbeth-30; panthenol; pyroglutamic acid and their salts and derivatives; amino acids, such as serine, proline, alanine, glutamate or arginine; ectoine and its derivatives; N -(2-hydroxyethyl)acetamide; N -lauroyl-pyrrolidonecarboxylic acid; N -lauroyl-L-lysine; N -alpha-benzoyl-L
  • agents stimulating healing, coadjuvant healing agents, agents stimulating re-epithelialization and/or coadjuvant re-epithelialization agents which can be contained in the liposomes in this invention are selected, for example and not restricted to, from the group formed by extracts of Aristolochia clematis, Centella asiatica, Rosa moschata, Echinacea angustifolia, Symphytum officinale, Equisetum arvense, Hypericum perforatum, Mimosa tenuiflora, Persea gratisima, Prunus africana, Tormentilla erectea, Aloe vera, Polyplant® Epithelizing [INCI: Calendula Officinalis, Hypericum Perforatum, Chamomilla Recutita, Rosmarinus Officinalis] marketed by Provital, Cytokinol® LS 9028 [INCI: Hydrolyzed Casein, Hydrolyzed Yeast
  • the agent stimulating the synthesis of dermal or epidermal macromolecules which can be contained in the liposomes of this invention is selected, for example and not restricted to, from the group formed by agents stimulating collagen synthesis, agents stimulating elastin synthesis, agents stimulating decorin synthesis, agents stimulating laminin synthesis, agents stimulating chaperone synthesis, agents stimulating hyaluronic acid synthesis, agents stimulating aquaporin synthesis, agents stimulating fibronectin synthesis, agents inhibiting collagen degradation, agents inhibiting elastin degradation, agents inhibiting serine proteases such as leukocyte elastase or cathepsin G, agents stimulating fibroblast proliferation, agents stimulating adipocyte proliferation, agents stimulating adipocyte differentiation, agents stimulating angiogenesis, agents stimulating glycosaminoglycan synthesis, DNA repair agents and/or DNA protecting agents, for example and not restricted to, extracts of Centella asiatica, Saccharomyces cerevisiae, Solanum tuberosum, Rosmarinus officinalis,
  • the elastase inhibiting agent which can be contained in the liposomes of this invention is selected, for example and not restricted to, from the group formed by Elhibin® [INCI: Glycine Soja (Soybean) Protein], Preregen® [INCI: Glycine Soja (soybean) Protein, Oxido Reductases] or Regu®-Age [INCI:Hydrolyzed Rice Bran Protein, Glycine Soja (Soybean) Protein, Oxido Reductases] marketed by Pentapharm/DSM, Juvenesce [INCI: Ethoxydiglicol and caprylic Triglycerid, Retinol, Ursolic Acid, Phytonadione, Ilomastat], MicromerolTM [INCI: Pyrus Malus Extract], Heather Extract [INCI: Calluna Vulgaris Extract], Extracellium® [INCI: Hydrolyzed Potato Protein] or FlavagrumTM PEG [INCI:
  • the matrix metalloproteinase inhibiting agent which can be contained in the liposomes of this invention is selected, for example and not restricted to, from the group formed by ursolic acid, isoflavones such as genistein, quercetin, carotenoids, lycopene, soy extract, cranberry extract, rosemary extract, Trifolium pratense (red clover) extract, Phormium tenax (New Zealand flax) extract, kakkon-to extract, sage extract, retinol and derivatives thereof, retinoic acid and derivatives thereof, sapogenins such as diosgenin, hecogenin, smilagenin, sarsapogenin, tigogenin, yamogenin and yucagenin among others, Collalift® [INCI: Hydrolyzed Malt Extract], Juvenesce [INCI: Ethoxydiglicol and Caprylic Triglyceride, Retinol,
  • the firming and/or redensifying and/or restructuring agent which can be contained in the liposomes of this invention is selected, for example and not restricted to, from the group formed by extracts of Malpighia punicitolia, Cynara scolymus, Gossypium herbaceum, Aloe Barbadensis, Panicum miliaceum, Morus nigra , Sesamum indicum , Glycine soja , Triticum vulgare , Pronalen® Refirming HSC [INCI: Triticum vulgare, Silybum Marianum, Glycine Soy, Equisetum Arvense, Alchemilla Vulgaris, Medicago Sativa, Raphanus Sativus] or Polyplant® Refirming [INCI: Coneflower, Asiatic Centella, Fucus, Fenugreek] marketed by Provital, Lanablue® [INCI: Sorbitol, Algae Extract] marketed
  • the anti-glycation agent which can be contained in the liposomes of this invention is selected, for example and not restricted to, from the group formed by Vaccinium angustifolium extracts, ergothioneine and derivatives thereof, lysine, Aldenine® [INCI: Hydrolized Wheat Protein, Hydrolized Soy Protein, Tripeptide-1], VilasteneTM [INCI: Lysine HCI, Lecithin, Tripeptide-10 Citrulline], dGlyageTM [INCI: Lysine HCI, Lecithin, Tripeptide-9 Citrulline] or Eyeseryl® [INCI: Acetyl Tetrapeptide-5] marketed by Lipotec, hydroxystilbenes and derivatives thereof, resveratrol or 3,3',5,5'-tetrahydroxystilbene among others.
  • the free radical scavenger and/or anti-atmospheric pollution agent, reactive carbonyl species scavenger which can be contained in the liposomes of this invention is selected, for example and not restricted to, from the group formed by tea extract, olive leaf extract, Rosmarinus officinalis extract or Eichhornia crassipes extract, benzopyrenes, vitamin C and derivatives thereof, vitamin E and derivatives thereof, in particular tocopherol acetate, ascorbyl glycoside, phenols and polyphenols, in particular tannins, tannic acid and ellagic acid, gallocatechol, anthocyanins, chlorogenic acid, stilbenes, indoles, cysteine-containing amino acid derivatives, in particular N -acetylcysteine, ergothioneine, S-carboxymethylcysteine, chelating agents, in particular EDTA or ethylenediamines, carotenoids, bioflavonoids, ubiquinon
  • the 5 ⁇ -reductase inhibiting agent which can be contained in the liposomes of this invention is selected, for example and not restricted to, from the group formed by extract of Cinnamommum zeylanicum , Laminaria saccharina, Spiraea ulmaria, Nettle Root, Pygeum africanum, Avena Sativa, Serenoa repens, extracts of the plants Arnica montana, Cinchona succirubra, Eugenia caryophyllata, Humulus lupulus, Hypericum perforatum, Mentha piperita , Rosmarinus officinalis, Salvia officinalis, Thymus vulgaricus, extract of plants of the genus Silybum, extract of plants which contain sapogenins and in particular extract of plants of the genus Dioscorea, retinoids and in particular retinol, sulfur and derivatives thereof, zinc salts and in particular zinc lactate, gluconate,
  • the lysyl- and/or prolyl-hydroxylase-inhibiting agent which may be contained in the liposomes of this invention is selected, for example and not restricted to, from the group formed by 2,4-diaminopyrimidine 3-oxide or 2,4-diamino-6-piperidinopyrimidine 3-oxide, among others.
  • the defensin synthesis stimulating agent which can be contained in the liposomes of this invention is selected, for example and not restricted to, from the group formed by extracts of or hydrolyzed Aloe Vera, Roast amaranth, Rehmannias radix, arnica, gardenia, carrot, orange, peach, pineapple, mint, gentian, hibiscus flower, walnut tree leaf, calabaza, peony, quinoa, boldo, rough bindweed, sunflower, elderberry, seaweed, hydrolyzed corn, hydrolyzed soy, hydrolyzed rice, valine and its isomers and derivatives, calcium and its salts, ⁇ -MSH and fragments contained in the amino acid sequence of ⁇ -MSH, vitamin A and its derivatives and precursors, vitamin D3 and its derivatives, jasmonic acid, fumaric acid, malic acid, citric acid, ascorbic acid, lactic acid, acetic acid, adepic acid, tartaric acid, c
  • the bactericidal and/or bacteriostatic agent and/or antimicrobial and/or germicidal agent and/or fungicidal agent and/or fungistatic agent and/or germ inhibitor which can be contained in the liposomes of this invention is selected, for example and not restricted to, from the group formed by macrolides, pyranosides, calcium channel blockers, for example and not restricted to, cinnarizine and diltiazem; hormones, for example and not restricted to, estril, analogues thereof or thyroxine and/or its salts, caprylyl glycol, imidazolidinyl urea, methyl 4-hydroxybenzoate [INCI: methylparaben], ethyl 4-hydroxybenzoate [INCI: ethylparaben], propyl 4-hydroxybenzoate [INCI: propylparaben], butyl 4-hydroxybenzoate [INCI: butylparaben], isobutyl
  • the NO-synthase inhibiting agent which can be contained in the liposomes of this invention is selected, for example and not restricted to, from the group formed by extracts of the plants Vitis vinifera, Olea europaea or Gingko biloba among others.
  • the desquamating agent and/or keratolytic agent and/or exfoliating agent which can be contained in the liposomes of this invention is selected, for example and not restricted to, from the group formed by hydroxy acids and derivatives thereof, ⁇ -hydroxyacids, in particular salicylic acid and derivatives thereof, or gentisic acid; ⁇ -hydroxyacids and its salts, such as glycolic acid, ammonium glycolate, lactic acid, 2-hydroxyoctanoic acid, ⁇ -hydroxycaprylic acid, mandelic acid, citric acid, malic acid or tartaric acid; ⁇ - and ⁇ -hydroxybutyric acids; polyhydroxy acids such as gluconic acid, glucuronic acid or saccharic acid; keto acids such as pyruvic acid, glyoxylic acid; pyrrolidinecarboxylic acid; cysteic acid and derivatives; aldobionic acids; azelaic acid and derivatives thereof such as azeloyl diglycinate; as
  • the anti-inflammatory agent and/or analgesic agent which can be contained in the liposomes of this invention is selected, for example and not restricted to, from the group formed by madecassoside extract, echinacea extract, amaranth seed oil, sandal wood oil, peach tree leaf extract, extract of Aloe vera, Arnica montana, Artemisia vulgaris, Asarum maximum, Calendula officinalis, Capsicum, Centipeda cunninghamii, Chamomilla recutita, Crinum asiaticum, Hamamelis virginiana, Harpagophytum procumbens, Hypericum perforatum, Lilium candidum, Malva sylvestris, Melaleuca alternifolia, Origanum majorana, Origanum vulgare, Prunus laurocerasus, Rosmarinus officialis, Salix alba, Silybum marianum, Tanacetum parthenium, Thymus vulgaris, Uncaria
  • the whitening or depigmenting agent of the skin which can be contained in the liposomes of this invention is selected, for example and not restricted to, from the group formed by extracts of Achillea millefolium, Aloe vera, Aradirachta indica, Asmuna japonica, Autocarpus incisus, Bidens pilosa, Broussonetia papyrifera, Chlorella vulgaris, Cimicifuga racemosa, Emblica officinalis, Glycyrrhiza glabra, Glycyrrhiza uralensis, Ilex purpurea, Ligusticum lucidum, Ligusticum wallichii, Mitracarpus scaber, Morinda citrifolia, Morus alba, Morus bombycis, Naringi crenulata, Prunus domesticus, Pseudostellariae radix, Rumex crispus, Rumex occidentalis, Sapindus
  • the melanin synthesis stimulating agent, propigmenting agent, self-tanning agent and/or melanocyte proliferation stimulating agent which can be contained in the liposomes of this invention is selected, for example and not restricted to, from the group formed by extracts of Citrus Aurantium Dulcis Fruit, Coleus forskohlii, Coleus Esquirolii, Coleus Scutellariodes, Coleus Xanthanthus, Ballota nigra, Ballota lanata, Ballota suavelens, Marrubium cylleneum, Cistus creticus, Amphiachyris amoena, Aster oharai, Otostegia fruticosa, Plectranthus barbatus, Halimium viscosum or Larix laricema, dihydroxyacetone and derivatives thereof, sugars, for example and not restricted to, melanin and derivatives thereof including melanin polymers and derivatives of melanin with a low molecular weight which are
  • the anti-wrinkle and/or anti-aging agent which can be contained in the liposomes in this invention is selected, for example and not restricted to, from the group formed by extracts of Vitis vinifera, Rosa canina, Curcuma longa, Iris pallida, Theobroma cacao, Ginkgo biloba, Leontopodium Alpinum or Dunaliella salina, Matrixyl® [INCI: Palmitoyl Pentapeptide-4], Matrixyl 3000® [INCI: Palmitoyl Tetrapeptide-7, Palmitoyl Oligopeptide], EssenskinTM [INCI: calcium hydroxymethionine], Renovage [INCI: teprenone] or Dermaxyl® [INCI: Palmitoyl Oligopeptide] marketed by Sederma, Vialox® [INCI: Pentapeptide-3], Syn®-Ake® [INCI: Dipeptide Diaminobutyroyl Benzylamide
  • the lipolytic agent or lipolysis stimulating agent, venotonic agent and/or anti-cellulite agent which can be contained in the liposomes of this invention is selected, for example and not restricted to, from the group formed by extracts of Bupleurum Chinensis, Cecropia Obtusifolia, Celosia Cristata, Centella Asiatica, Chenopodium Quinoa, Chrysanthellum Indicum, Citrus Aurantium Amara, Coffea Arabica, Coleus Forskohlii, Commiphora Myrrha, Crithmum Maritimum, Eugenia Caryophyllus, Ginkgo Biloba, Hedera Helix (ivy extract), Hibiscus Sabdariffa, Ilex Paraguariensis, Laminaria Digitata, Nelumbium Speciosum, Paullinia Cupana, Peumus Boldus, Phyllacantha Fibrosa, Prunella Vulgaris, Prunus Amygdalus D
  • the heat shock protein synthesis stimulating agent which can be contained in the liposomes of this invention is selected, for example and not restricted to, from the group formed by extracts of Opuntia ficus indica, Salix alba, Lupinus spp ., Secale cereale, extracts of red algae from the Porphyra genus, extracts of crustaceans from the Artemia genus, jojoba seed oil, grape seed extracts, green tea extracts, geranylgeranylacetone, celastrol, zinc and its salts, 2-cyclopenten-1-one, proteasome inhibitors, for example and not restricted to, bortezomib; prostaglandins and derivatives thereof, hydroxylamine and derivatives thereof, for example and not restricted to, bimoclomol; chalcone and derivatives thereof, hyperosmotic agents, for example and not restricted to, sorbitol and derivatives thereof, mannitol and derivatives thereof or glycerol and derivatives thereof
  • the hair growth inducing or hair loss retardant agent which can be contained in the liposomes of this invention is selected, for example and not restricted to, from the group formed by the extracts of Tussilago farfara or Achillea millefolium, nicotinic acid esters such as C 3 -C 6 alkyl nicotinates such as methyl or hexyl nicotinate, benzyl nicotinate, or tocopheryl nicotinate; biotin, 5 ⁇ -reductase-inhibiting agents, anti-inflammatory agents, retinoids, for example and not restricted to, All-trans-retinoic acid or tretinoin, isotretinoin, retinol or vitamin A, and derivatives thereof, such as acetate, palmitate, propionate, motretinide, etretinate and zinc salt of trans-retinoic acid; anti-bacterial agents, calcium channel blockers, for example and not restricted to, cin
  • the body hair growth inhibiting or retardant agent which may be contained in the liposomes of this invention is selected, for example and not restricted to, from the group formed by activin or activin agonists, flavonoids such as quercetin, curcumin, galangin, fisetin, myricetin, apigenin; propyl gallate, nordihydroguaiaretic acid, caffeic acid, tyrosine kinase inhibitors such as lavendustin, erbstatin, tyrphostins, benzoquinone-ansamycin herbimycin A, thiazolidinediones, phenazocine, 2,3-dihydro-2-thioxo-1H-indol-3-alcanoic acids, phenothiazine derivatives such as thioridazine; sphingosine and derivatives thereof, staurosporine and derivatives thereof, glycyrrhetinic acid, lauryl iso
  • the cosmetic and/or absorbent and/or body odor masking deodorant and/or antiperspirant agent, perfuming substance and/or perfumed oil which can be contained in the liposomes of this invention is selected, for example and not restricted to, from the group formed by the complex salt of ricinoleic acid, Styrax, derivatives of abiotic acid, sage essence, chamomile essence, carnation essence, lemon balm essence, mint essence, cinnamon leaf essence, lime flower essence, juniper berry essence, vetiver essence, olibanum essence, galbanum essence, labdanum essence, lavender essence, peppermint essence, bergamot orange, dihydromyrcenol, lilial, lyral, citronellol, lemon essence, mandarin essence, orange essence, lavender essence, muscat, geranium bourbon essence, aniseed, cilantro, cumin, juniper, extracts of fleur-de-lis, lilac, roses
  • the antioxidant which can be contained in the liposomes of this invention is selected, for example and not restricted to, from the group formed by butylhydroxyanisole, 2,6,-di-tert-butyl-4-methylphenol, propyl gallate, probucol, polyphenoles, ascorbic acid and its salts, enzymes such as catalase, superoxide dismutase and peroxidases; citric acid, citrates, monoglyceride esters, calcium metabisulfate, lactic acid, malic acid, succinic acid, tartaric acid, vitamin A or ⁇ -carotene, vitamins E and C, zinc, copper, mannitol, reduced glutathione, carotenoids such as cryptoxanthin, astaxanthin and lycopene; cysteine, uric acid, taurine, tyrosine, lutein, zeaxanthin, N -acetyl-cysteine, carnosine, ⁇ -glutamylc
  • the agent inhibiting sweat-degrading enzymes which can be contained in the liposomes of this invention is selected, for example and not restricted to, form the group formed by trialkyl citrates such as trimethyl citrates, tripropyl citrate, triisopropyl citrate, tributyl citrate or triethyl citrate; lanosterine sulfate or phosphate, cholesterin, campesterin, stigmasterin and sitosterin; dicarboxylic acids and their esters, such as glutaric acid, monoethyl glutarate, diethyl glutarate, adipic acid, monoethyl adipate, diethyl adipate; malonic acid and diethyl malonate, hydroxycarboxylic acids and their esters such as malic acid, tartaric acid or diethyl tartrate, zinc glycinate and/or mixtures thereof.
  • trialkyl citrates such as trimethyl citrates, tripropyl citrate,
  • the agent capable of filtering UV rays which can be contained in the liposomes of this invention is selected, for example and not restricted to, from the group formed by organic or mineral photoprotective agents active against A and/or B rays such as substituted benzotriazoles, substituted diphenylacrylates, organic nickel complexes, umbelliferone, urocanic acid, biphenyl derivatives, stilbene, 3-benzylidene camphor, and derivatives thereof such as 3-(4-methylbenzylidene)camphor; derivatives of 4-aminobenzoic acid, 2-ethylhexyl 4-( dimethylamino)benzoate, 2-octyl 4-(dimethylamino)benzoate and amyl 4-(dimethylamino)benzoate; cinnamic acid esters, such as 2-ethylhexyl 4-methoxycinnamate or diethylamino hydroxybenzoyl hexyl benzoate
  • the agent stimulating or regulating keratinocyte differentiation which can be contained in the liposomes of this invention is selected, for example and not restricted to, from the group formed by minerals such as calcium, retinoids such as retinol or tretinoin, analogues of vitamin D3 such as calcitriol, calcipotriol or tacalcitol, lupine (Lupinus albus) extract such as that marketed by SILAB under the name Structurin® [INCI: Hydrolyzed Lupine Protein], ⁇ -sitosterol sulfate, such as that marketed by Vincience/ISP with the name Phytocohesine PSP® [INCI: Sodium Beta-sitosterol Sulfate], maize (Zea Mays) extract such as that marketed by Solabia with the name Phytovityl C® [INCI: Water (Aqua), Zea Mays Extract], Helix Aspersa Müller glycoconjugates and/
  • the muscle relaxant, agent inhibiting muscle contraction, agent inhibiting acetylcholine receptor clustering and/or anticholinergic agent which can be contained in the liposomes of this invention is selected, for example and not restricted to, from the group formed by extracts of Atropa belladonna, Hyoscyamus niger, Mandragora officinarum, Chondodendron tomentosum, plants of the Brugmansia genus, or the Datura genus, Clostridium botulinum toxin, peptides derived from the protein SNAP-25 or InylineTM [INCI: Acetyl Hexapeptide-30] marketed by Lipotec, baclofen, carbidopa, levodopa, bromocriptine, chlorphenesin, chlorzoxazone, donepezil, mephenoxalone, reserpine, tetrabenazine, dantrolene,
  • microfluidized liposomes of this invention can be a final composition on their own, available for application without having to carry out any kind of concentration, solution, dilution, dispersion, pulverization, spraying procedure or any other similar procedure known by the person skilled in the art, or an intermediate composition to which one or several of the previous procedures will be carried out or any other procedure known by the person skilled in the art with the aim of obtaining a composition, wherein this composition is a final composition.
  • composition which comprises the liposomes of this invention is used for the treatment of textile materials and can be presented in liquid form, such as washing agents, sprays, liquid soap or gels, or also in solid form, such as powder, granules or compact products.
  • these compositions contain other components, for example and not restricted to, surfactants, agents which increase percutaneous absorption, agents for the prior treatment of textile materials, agents for the treatment of marks, abrasives, water softeners, fabric softeners, solvents or solubilizing agents, agents for the variation of touch and finish, dirt-repelling agents, antistatic agents, enzymes, agents which aid ironing, color and/or colorant brightening agents, shine agents, optical clearing agents, graying inhibitors or compounds for the loosening of dirt, color transfer inhibitors, phobizing and impregnating agents, swelling or thickening agents, consistency-generating agents, silicon agents, agents which increase the percutaneous absorption of liposomes, whitening agents and textile material bleaching activators, hydrophilization agents or mixtures
  • the surfactant which can be contained in the composition is selected from among the surfactants mentioned above which form mixed liposomes.
  • the surfactant in the composition is an anionic surfactant, and more preferably it is selected from the group formed by sulfonates such as alkylbenzene sulfonates, alkylnaphthalene sulfonates, ethoxylated fatty acid sulfonates, aliphatic sulfonates, hydroxyalkane sulfonates, alkyl glyceryl ether sulfonates, perfluorooctane sulfonate; alkyl sulfosuccinates, alkyl sulfoacetates, alkyl sulfates such as sodium and ammonium lauryl sulfate, ethoxylated alkyl sulfates, fatty ester sulfates, ethoxylated fatty
  • the agent which increases the percutaneous absorption of the liposomes contained in the composition is selected, for example and not restricted to, from the group formed by dimethyl sulfoxide, dimethylacetamide, dimethylformamide, surfactants, azona (1-dodecylazacycloheptan-2-one), alcohol, urea, ethoxydiglycol, acetone, propylene glycol or polyethylene glycol among others.
  • the composition is a washing agent or a spray.
  • the touch and finish variation agent or dirt-repelling agent which can be contained in the composition is selected, for example and not restricted to, from the group formed by terephthalates and fluorine compounds.
  • the composition is a washing agent or a spray.
  • the water softening agent which can be contained in the composition is selected from the group formed by zeolites, montmorillonite, silicates, aluminosilicates, alkali metal polyphosphates such as sodium hexametaphosphate, tetrasodium pyrophosphate or sodium tripolyphosphate; monosodium phosphate, disodium phosphate, trisodium phosphate; ethylenediamine derivatives such as EDTA; nitriloacetic acid, alkali salts such as carbonate and sodium bicarbonate; ammonium acetate, sodium propionate, acrylic acid and polyacrylate polymers, inorganic peroxides such as percarbonate or perborate; citric acid and its salts, malic acid, sulfonic acid, gluconic acid, phosphonic acid, tetraacetic acid and/or mixtures thereof.
  • the composition is a washing agent or a spray.
  • the agent which aids ironing which can be contained in the composition is selected from the group formed by silicone oils or synthetic hydrocarbons.
  • the silicone is selected, for example and not restricted to, from the group formed by polydimethylsiloxanes, poly methyl phenyl siloxanes, simethicones, cyclic silicones, compounds of silicone modified with amine groups, fatty acids, alcohol, polyether, epoxy, fluorine, glycoside and/or alkyl.
  • the composition is a washing agent or a spray.
  • the optical clearing agent ironing which can be contained in the composition is selected, for example and not restricted to, from the group formed by derivatives of diaminostilbene disulfonic acid, such as 4,4'-bis(2-aniline-4-morpholine-1,3,5-triazinyl-6-amino)stilbene-2,2'-disulfonic acid salts, substituted diphenyl stirenes, such as 4,4'-bis(2-sulfostyryl)-diphenyl alkali salts, 4,4'-bis(4-chloro-3-sulfostyryl)-diphenyl, or 4-(4-chlorostyryl)-4'-(2-sulfostyryl)-diphenyl and/or mixtures thereof.
  • the composition is preferably a washing agent or a spray.
  • the graying inhibitor or the compound for the loosening of dirt which can be contained in the composition is selected, for example and not restricted to, from the group formed by hidrosoluble colloids, such as cola, gelatin, ether carboxylic acid salts, ether sulfonic acids of starch or cellulose, sulfate salt acids of cellulose or starch, hydrosoluble polyamides which contain acid groups, aldehyde starches, cellulose ethers such as carboxymethylcellulose, methylcellulose, hydroxyalkylcellulose, methylhydroxyethylcellulose, methylhydroxypropylcellulose, methylcarboxymethylcellulose and mixtures thereof.
  • the composition is preferably a washing agent or a spray.
  • the phobizing and impregnating agent which can be contained in the composition is selected, for example and not restricted to, from the group formed by starch derivatives for the stiffening of textile materials.
  • the composition is preferably a washing agent or a spray.
  • the enzyme which can be contained in the composition is selected from the group formed by oxidases, proteases, lipases, cutinases, amylases, pullulanases, cellulases, hemicellulases, xylanases and peroxidases, for example and not restricted to, active enzymatic products obtained from fungi or bacteria, such as Bacillus subtilis, Bacillus licheniformis, Streptomyces griseus, Humicola lanuginosa, Humicola insolens, Pseudomonas pseudoalcaligenes or Pseudomonas cepacia, among others.
  • the composition is preferably a washing agent or a spray.
  • the swelling or thickening agent which can be contained in the composition is selected, for example and not restricted to, from the group formed by montmorillonites, chalk, zeolites, silicic acids, bentonites, polycarboxylates and its acids, polyacrylates, polyacetals, dextrins, phosphonates, agar, carraghenates, gum tragacanth, xanthan gum, gum arabic, alginates, pectins, polyoses, guar flour, carob seed flour, starch, gelatin, casein, vinyl polymers, polyethers, polyimines, polyamides, polyurethanes, vinyl acetate/crotonic acid copolymers, vinylpyrrolidone/vinyl acrylate copolymers, vinyl acetate/butyl maleate/ isobornyl acrilate copolymers, methylvinylether/maleic anhydride acid copolymers and their esters, polyvinylpyrrolidone,
  • the consistency-generating agent which can be contained in the composition is selected, for example and not restricted to, from the group formed by fatty alcohols or hydroxy fatty alcohols with from 12 to 22 carbon atoms, partial glycerides, fatty acids or hydroxy fatty acids, alkyl oligo glucosides and/or fatty acid N -methyl glucamides, polyglycerin poly-12-hydroxy stearates or mixtures thereof.
  • the composition is preferably a washing agent or a spray.
  • the whitening or textile material bleaching activator which can be contained in the composition is selected, for example and not restricted to, from the group formed by transition metal salts, or transition metal complexes which intensify the bleaching, such as manganese carbonyl complexes, iron, cobalt, ruthenium or molybdenum, bleach catalysts of manganese complexes, iron, cobalt, ruthenium, molybdenum, titanium, vanadium or copper with amine ligands, peroxo carboxyl aliphatic acids preferably with from 1 to 10 carbon atoms, perbenzoic acid, polyacylated alkylene diamines, such as tetraacetylethylenediamine (TAED), acylated triazine derivatives, such as 1,5-diacetyl-2,4-dioxohexahydro-1,3,5-triazine (DADHT), acylated glycoluril, such as tetraacetylgly
  • peroxybenzoic acid and derivatives thereof substituted in the ring can be used, such as alkyl peroxybenzoic acids; peroxy- ⁇ -naphthoic acid and magnesium monoperphthalate, aliphatic peroxy acids or substituted aliphatic acids such as peroxylauric acid, peroxystearic acid, ⁇ -phthalimido peroxycapronic acid (phthalimido peroxy hexanoic acid PAP), o-carboxy benzamido peroxycapronic acid, N -nonenylamidoperadipic acid and N- nonenylamidopersuccinates, and aliphatic peroxy dicarboxylic acids (preferably with 1 to 10 carbon atoms, in particular 2 to 4 carbon atoms) and araliphatic peroxy dicarboxylic acids, such as 1,12-diperoxycarboxylic acid, 1,9-diperoxyazelaic acid, diperoxysebacic acid, diperoxy brassylic acid, diper
  • substances which release chlorine or bromine can also be used as bleaching agents.
  • suitable materials which release chlorine or bromine the following are considered, for example: heterocyclic N -bromo- and N -chloro amides, for example, trichloroisocyanuric acid, tribromoisocyanuric acid, dibromoisocyanuric acid and/or dichloroisocyanuric acid (DICA) and/or their salts with cations, such as potassium and sodium.
  • hydantoin such as 1,3-dichloro-5,5-dimethylhydantoin are equally suitable.
  • composition is a washing agent or a spray.
  • the hydrophilization agent which may be contained in the composition is selected, for example and not restricted to, from the group formed by alcohols, polyols, polyethylene glycols, alkanolamines, glycol mono- or polyvalent ether, carboxylates or copolymers in blocks of oxide of ethylene oxide-propylene, provided that they are miscible with water.
  • the hydrophilized agents are preferably selected from ethanol, n - or iso -propanol, butanols, ethylene glycol methyl ether, ethylene glycol ethyl ether, ethylene glycol propyl ether, ethylene glycol mono-n-butyl ether, diethylene glycol methyl ether, diethylene glycol ethyl ether, propylene glycol methyl ethyl- or -propyl ether, dipropylene glycol monomethyl- or -ethyl ether, diisopropylene glycol monomethyl- or -ethyl ether, methoxy, ethoxy, or butoxytriglycol, 1-butoxyethoxy-2-propanol, 3-methyl-3-methoxybutanol, propylene-glycol- t -butyl-ether, sorbitol, mannitol, or mixtures thereof.
  • the composition is a washing agent or a spray.
  • textile materials are understood to be fabrics, non-woven fabrics, garments and medical devices.
  • the preferred fabrics, non-woven fabrics, garments and medical devices are bandages, gauzes, t-shirts, socks, tights, underwear, girdles, gloves, diapers, sanitary napkins, dressings, bedspreads, wipes, hydrogels, adhesive patches, non-adhesive patches, microelectric patches and/or face masks.
  • the term "aging” relates to the changes experienced by the skin with age (chronoaging) or due to exposure to the sun (photoaging) or to environmental agents such as tobacco smoke, extreme climatic conditions of cold and wind, chemical pollutants or pollution, and includes all the external visible changes as well as those noticeable by palpation, for example and not restricted to, the development of discontinuities on the skin such as wrinkles, fine lines, furrows, irregularities or roughness, increase in the size of pores, loss of elasticity, loss of firmness, loss of smoothness, loss of the capacity to recover from the deformation, sagging of the skin such as sagging cheeks, the appearance of bag under the eyes or the appearance of a double chin among others, changes to the color of the skin such as marks, reddening, bags under the eyes, appearance of hyperpigmented areas such as age spots or freckles among others, anomalous differentiation, hyperkeratinization, elastosis, keratosis, hair loss, orange-peel skin, loss of collagen structure
  • the sample was passed through a microfluidizer for a cycle at an entrance pressure of 8 Mpa and 86.18 Mpa (80 bar and 12500 psi) on exit.
  • the liposomes obtained were added to Luviquat HMM552 [INCI: Polyquaternium-16] in a cationic liposome:polymer ratio of 1.5:1 under light stirring.
  • the liposomes obtained were added to Luviquat HMM552 [INCI: Polyquaternium-16] in a cationic liposome:polymer ratio of 1.5:1 under light stirring.
  • the liposomes were obtained in the same way as in example 1 but instead of Antarcticine®, Liporeductyl® (ingredients from phase A) was used and the same ingredients and quantities as in the other phases.
  • INGREDIENT INCI Nomenclature
  • BUTCHERBROOM RUSCUS ACULEATUS
  • ROOT EXTRACT MALTODEXTRIN
  • SILICA 0.57 A LECITHIN 0.83
  • a CAFFEINE 0.59 A TEA-HYDROIODIDE 0.44 A CARNITINE 0.30 A BUTYLENE GLYCOL, WATER (AQUA), IVY (HEDERA HELIX) 0.38 A ESCIN 0.74
  • a TRIPEPTIDE-1 0.001
  • CARRAGEENAN CHONDRUS CRISPUS
  • CAPRYLYL GLYCOL 0.09
  • PHENOXYETHANOL 0.09
  • the liposomes obtained were added to Luviquat HMM552 [INCI: Polyquaternium-16] in a cationic liposome:polymer ratio of 1.5:1 under light stirring.
  • the liposomes were obtained in the same way as in example 1 but instead of Antarcticine®, Serilesine® (ingredients from phase A) was used and the same ingredients and quantities as in the other phases.
  • INGREDIENT ICI Nomenclature
  • % IN WEIGHT A GLYCERIN 1.00
  • AQUA (WATER) q.s.p. 100
  • the liposomes obtained were added to Luviquat HMM552 [INCI: Polyquaternium-16] in a cationic liposome:polymer ratio of 1.5:1 under light stirring.
  • INGREDIENT (INCI Nomenclature) % IN WEIGHT A HYALURONIC ACID 0.05 B DIETHYLAMINOHYDROXYBENZOYL HEXYL BENZOATE 8.50 C 1,3-PROPANEDIOL 8.50 D PHENOXYETHANOL 1.70 E AQUA (WATER) q.s.p. 100 F LECITHIN 10.00 G PEG-8 CAPRYLIC / CAPRIC GLYCERIDES 4.00
  • the liposomes obtained were added to Luviquat HMM552 [INCI: Polyquaternium-16] in a cationic liposome:polymer ratio of 1.5:1 under light stirring.
  • PreventheliaTM (ingredients from phase A), part of the water, Zemea [INCI: 1,3-propanediol], Labrasol [INCI: PEG-8 Caprylic /Capric Glycerides] and phenoxyethanol (ingredients B to E) were added to a suitable vessel. When all the previous components had dissolved Leciflor 100IP [INCI: Lecithin] (ingredient F) was added slowly under intense stirring until fully dissolved.
  • the sample was passed through a microfluidizer for 3 cycles at an entrance pressure of 8 MPa and 86.18 MPa on exit.
  • the liposomes obtained were added to Luviquat HMM552 [INCI: Polyquaternium-16] in a cationic liposome:polymer ratio of 1.5:1 under light stirring.
  • composition of a spray containing liposomes which contain Antarcticine ® bound to cationic polymers which contain Antarcticine ® bound to cationic polymers
  • the sample was passed through a microfluidizer for 3 cycles at an entrance pressure of 8 MPa and 86.18 MPa (80 bar and 12500 psi) on exit.
  • the liposomes obtained were added to Luviquat HMM552 [INCI: Polyquaternium-16] in a cationic liposome:polymer:water ratio of 8:1:1 under light stirring.
  • composition of a spray containing liposomes which contain Antarcticine ® bound to cationic polymers which contain Antarcticine ® bound to cationic polymers
  • the sample was passed through a microfluidizer for 3 cycles at an entrance pressure of 8 MPa and 86.18 MPa (80 bar and 12500 psi) on exit.
  • the liposomes obtained were added to Luviquat HMM552 [INCI: Polyquaternium-16] in a cationic liposome:polymer ratio of 4:1 under light stirring.
  • the liposomes from example 3 were diluted in 50 mL water baths at 1%, 5%, 10% and 25% in weight.
  • Different textile materials such as polyamide (PA), cotton (CO 100%), polyester (PES), non-woven viscose (VISCOSA) and tights (TIGHTS), were submerged in each of the previous baths with ratios of textile material weight/bath of 1/25, 1/50 and 1/100 and they were kept submerged for 10 minutes at room temperature without stirring.
  • the textile materials were dried by being hung out according to standard UNE-EN ISO 6330 after the bath and after each wash. Typical drying times were 24 hours at room temperature.
  • Figure 5a shows an image of the mica substrate on its own. As the mica does not present any distortion on its structure, the color pattern is homogeneous. However, for the liposomes in example 2, figure 5b shows a layer with series of irregularities or small peaks which are the polyquaternium-16 layer or film on the mica substrate. Furthermore, vesicular structures in a clearer color than the liposomes to which the polyquaternium-16 polymeric chains are bound were observed.
  • the liposomes obtained in example 3 were taken and 100 ⁇ L of 2% weight aqueous solution of these liposomes was applied directly with a micropipette to a piece of cotton fabric with a surface area of 1,77 cm 2 .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Textile Engineering (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (11)

  1. Verwendung von mikrofluidisierten Liposomen, umfassend mindestens eine Doppelschicht von mindestens einem Phospholipid, enthaltend kosmetische und/oder dermopharmazeutische Wirkstoffe und/oder Hilfsstoffe, wobei die Liposomen mit kationischen Polymeren zur Behandlung von Textilien verbunden sind, wobei diese Polymere ein Netzwerk über die Oberfläche der Textilien bilden, wenn sie in Kontakt mit Textilien gebracht werden, wobei das Netzwerk mehrere Liposomen innerhalb des gleichen kationischen Netzwerks einschließt, wobei die Größe des kationischen Polymers von 600 bis 1 700 nm reicht und die Größe der Liposomen kleiner als 200 nm ist,
    wobei das kationische Polymer aus der Gruppe ausgewählt wird, bestehend aus kationischer Cellulose, quaternisierter Hydroxyethylcellulose, kationischer Stärke, Copolymeren von Diallylammonium und Acrylamidsalzen, quaternisierten Vinylpyrrolidon/Vinylimidazol-Polymeren, Polyquaternium-Polymeren und -Copolymeren, Pfropfcopolymeren mit einem Cellulose-Backbone und quatären Ammoniumgruppen, quaternisierten Kollagenpolypeptiden, hydrolysiertem Hydroxypropyl-Iauryldiammonium-Kollagen, quaternisierten Weizenpolypeptiden, kationischen Silikonpolymeren, Silikonquaternium-22, Adipinsäure und Dimethylaminohydroxypropyldiethylenetriamin-Copolymeren, Copolymeren von Acrylsäure mit Dimethyldiallylammoniumchlorid, kationischem Chitin, Chitosan, kationischem Guaran, Guar-hydroxypropyltriammonium, quartären Ammoniumsalz-Polymeren, quaternisierten Polysaccharid-Polymeren von Agar, kationischer Gelatine, Polyamiden, kationischen Polymethacrylaten, kationischen Polyaminosäuren, Polyethylenimin und/oder Gemischen davon.
  2. Verwendung nach Anspruch 1, wobei das Phospholipid der mikrofluidisierten Liposome ein Phosphoglycerid ist.
  3. Verwendung nach Anspruch 2, wobei das Phosphoglycerid aus der Gruppe ausgewählt ist, bestehend aus Phosphatidylserin, Phosphatidylinositol, Phosphatidylethanolamin, Phosphatidylcholin, Phosphatidsäure, Phosphatidylglycerol, Diphosphatidylglycerol, Phosphorylcholin, Cardiolipin, Eilecithin, Sojalecithin, Sonnenblumenlecithin, ihren Fettsäureestern, Hydrierungsprodukten und Gemischen davon.
  4. Verwendung nach einem der vorhergehenden Ansprüche, wobei das mikrofluidisierte Liposom durch ein oder mehr Phospholipide und einem oder mehr Tenside gebildet ist.
  5. Verfahren nach Anspruch 4, wobei das Tensid aus der Gruppe ausgewählt ist, bestehend aus nichtionischen Tensiden, amphoteren Tensiden, anionischen Tensiden, kationischen Tensiden und Gemischen davon.
  6. Verwendung nach einem der vorhergehenden Ansprüche, wobei der kosmetische und/oder dermopharmazeutische Wirkstoff und/oder Hilfsstoff aus einer Gruppe ausgewählt ist, bestehend aus Tensiden, Feuchthaltemitteln oder Substanzen, die Feuchtigkeit speichern, Befeuchtungsmitteln, Erweichungsmitteln, Agenzien, die Heilung fördern, Heilungshilfsstoffen, Agenzien zur Stimulierung von Re-Epithelisierung, Hilfsstoffen zur Re-Epithelisierung, Agenzien zur Stimulierung der Synthese von dermalen oder epidermalen Makromolekülen, bildenden und/oder verdichtenden und/oder restrukturierenden Agenzien, Cytokinwachstumsfaktoren, Agenzien, die auf den Kapillarkreislauf und/oder die -mikrozirkulation wirken, Anti-Glykationsmitteln, Radikalfängern und/oder -agenzien, Anti-Luftverschmutzungs-Agenzien, reaktive Carbonyl-Spezies-Fängern, 5a-Reductase hemmenden Agenzien, lysyl- und/oder Prolylhydroxylase hemmenden Agenzien, Defensinsynthese stimulierenden Agenzien, bakteriziden Agenzien und/oder bakteriostatischen Agenzien und/oder antimikrobiellen Agenzien und/oder keimtötenden Agenzien und/oder fungiziden Agenzien und/oder fungistatischen Agenzien und/oder keimhemmenden Agenzien, antiviralen Agenzien, antiparasitären Agenzien, antihistaminischen Agenzien, NO-Synthase hemmenden Agenzien, Desquamationsmitteln oder keratolytischen Agenzien und/oder exfolierenden Agenzien, komedolytischen Agenzien, Anti-Psoriasis-Agenzien, entzündungshemmenden Agenzien und/oder Analgetika, Anästhetika, Antifalten- und/oder Anti-Aging-Mitteln, kosmetischen Deodorants und/oder Absorptionsmitteln und/oder Körpergeruch überdeckenden Deodorants, Antiperspiranten, parfümierenden Substanzen und/oder parfümierten Ölen und/oder isolierten aromatischen Verbindungen, Antioxidationsmitteln, Agenzien, die Gefäßdurchlässigkeit hemmen, hydrolytischen epidermalen Enzymen, aufhellenden oder hautdepigmentierenden Agenzien, Agenzien, die schweißzersetzende Enzyme hemmen, UV-Strahlen filternden Agenzien, Agenzien, die die Differenzierung von Keratinozyten stimulieren oder regulieren, juckreizhemmenden Agenzien, Agenzien, die die Synthese von Melanin stimulieren oder hemmen, Pigmentierungsmitteln, Selbstbräunungsmitteln, Agenzien, die die Proliferation von Melanozyten stimulieren, flüssigen Treibmitteln, Vitaminen, Aminosäuren, Proteinen, Biopolymeren, gelierenden Polymeren, hautentspannenden Agenzien, Agenzien, die Tränensäcke reduzieren oder behandeln können, Agenzien für die Behandlung und/oder Pflege von empfindlicher Haut, astringierenden Agenzien, Agenzien, die die Talgproduktion regulieren, Agenzien gegen Dehnungsstreifen, lipolytischen Agenzien oder Agenzien, die Lipolyse stimulieren, veinotonischen Agenzien, Anti-Cellulite-Mitteln, beruhigenden Agenzien, Agenzien, die auf Zellmetabolismus wirken, Agenzien, um dermo-epidermische Bindung zu verbessern, Agenzien, die Haarwachstum induzieren, oder Haarverlust verzögernden Agenzien, Körperhaarwachstum hemmenden oder verzögernden Agenzien, Hitzeschockproteinsythese stimulierenden Agenzien, Muskelrelaxanzien, Muskelkontraktion hemmenden Agenzien, Agenzien, die die Aggregation von Acetylcholinrezeptoren hemmen, anticholinergen Agenzien, Elastase hemmenden Agenzien, Matrix-Metalloproteinase hemmenden Agenzien, Chelatin bildenden Agenzien, Pflanzenextrakten, ätherischen Ölen, Meeresextrakten, Mineralsalzen, Zellextrakten, emulgierenden Agenzien, Agenzien, die die Synthese von Lipiden und Komponenten der Hornhaut stimulieren, Agenzien, die von einem Biofermentationsverfahren erhalten wurden und/oder Gemischen davon.
  7. Zusammensetzung, die mikrofluidisierte Liposome nach einem der vorhergehenden Ansprüche umfasst.
  8. Zusammensetzung nach Anspruch 7, die Tenside, Agenzien für die Vorbehandlung von Textilien, Agenzien zur Behandlung von Flecken, Schleifmittel, Wasserenthärter, Textilweichmacher, Lösungsmittel oder Solubilisierungsmittel, Agenzien für die Variation von Griff und Finish, schutzabweisende Agenzien, antistatische Agenzien, Enzyme, Agenzien zur Bügelhilfe, Farb- und/oder farbaufhellende Mittel, Glanzmittel, optische Klärmittel, Vergrauungsinhibitoren oder Verbindungen zum Lockern von Schmutz, Farbübertragungsinhibitoren, Hydrophobierungs- und Imprägniermittel, Quell- oder Verdickungsmittel, Konsistenz erzeugende Agenzien, Silikone, Agenzien, die die perkutane Absorption von Liposomen erhöhen, Bleichmittel und Bleichaktivatoren für Textilien, Hydrophilierungsmittel oder Gemische davon umfasst.
  9. Zusammensetzung nach einem der Ansprüche 7 oder 8, die in der Form eines Waschmittels und/oder -sprays präsentiert ist.
  10. Behandelte Textilien aus Anspruch 1 zur Verwendung in der dermopharmazeutischen Behandlung und/oder Pflege von Haut, Haar und/oder Kopfhaut.
  11. Verwendung von behandelten Textilien aus Anspruch 1 für die kosmetische Behandlung von Pflege von Haut, Haar und/oder Kopfhaut.
EP11704413.1A 2010-02-18 2011-02-18 Verwendung von liposomen zur behandlung von textilien Active EP2536815B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201030229A ES2373704B1 (es) 2010-02-18 2010-02-18 Liposomas para el tratamiento de materiales textiles.
PCT/EP2011/000778 WO2011101153A1 (en) 2010-02-18 2011-02-18 Liposomes for the treatment of textile materials

Publications (2)

Publication Number Publication Date
EP2536815A1 EP2536815A1 (de) 2012-12-26
EP2536815B1 true EP2536815B1 (de) 2018-07-11

Family

ID=43969372

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11704413.1A Active EP2536815B1 (de) 2010-02-18 2011-02-18 Verwendung von liposomen zur behandlung von textilien

Country Status (4)

Country Link
US (1) US9717659B2 (de)
EP (1) EP2536815B1 (de)
ES (2) ES2373704B1 (de)
WO (1) WO2011101153A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2507752B (en) * 2012-11-07 2017-09-13 Intelligent Fabric Tech Plc fabric softener
AU2013371414B2 (en) 2013-01-07 2016-11-03 Elc Management Llc Method and compositions for improving selective catabolysis and viability in cells of keratin surfaces
US20140205550A1 (en) * 2013-01-23 2014-07-24 Hugo A. Corstjens Method for Cosmetically Treating Caspase-14 Deficiency
ITMI20130151A1 (it) * 2013-02-01 2014-08-02 Emenem S P A "metodo per caricare un tessuto o un indumento con una composizione per il rilascio controllato di principi attivi, detta formulazione, sua preparazione e sue applicazioni"
US20150050331A1 (en) * 2013-04-25 2015-02-19 Novo Solutions Md, Llc Method for making a topical composition comprising growth factors derived from human umbilical cord blood platelets
US9801900B2 (en) 2013-11-22 2017-10-31 Mary Kay Inc. Compositions for sensitive skin
WO2015088663A1 (en) * 2013-12-09 2015-06-18 Novo Solutions Md, Llc Method for making a topical composition comprising growth factors derived from human umbilical cord blood platelets
CN103767070B (zh) * 2014-01-15 2015-08-05 中国烟草总公司广东省公司 角鲨烯与虾青素组合物液态前体脂质体的制备方法及其降基减害应用
CN103815545B (zh) * 2014-01-15 2015-09-30 华南农业大学 角鲨烯与茶多酚组合物多囊脂质体的制备方法及其降基减害应用
AU2016347878A1 (en) * 2015-11-02 2018-05-10 Lubrizol Advanced Materials, Inc. Composition for protecting the skin against the effects of pollution and use thereof
FR3044223B1 (fr) * 2015-11-30 2019-05-24 Laboratoires M&L Composition cosmetique et utilisation
JP6169240B1 (ja) * 2016-10-28 2017-07-26 サンスター株式会社 リノール酸含有組成物
EP3366353A1 (de) * 2017-02-28 2018-08-29 Colgate-Palmolive Company Zusammensetzung zur persönlichen pflege enthaltend ein konservierungssystem
US20180311162A1 (en) * 2017-05-01 2018-11-01 Shen Wei (Usa) Inc. Skin barrier enhancing article and manufacturing method
US9943503B1 (en) * 2017-10-19 2018-04-17 Edward Wick Pharmaceutical composition for treating bacterial and viral infections
CN109161885B (zh) * 2017-11-14 2019-12-17 西南交通大学 一种铝合金表面抗菌功能化改性方法
WO2019111415A1 (ja) * 2017-12-08 2019-06-13 ワミレスコスメティックス株式会社 カチオン化ベシクル及びその組成物
ES2754476B2 (es) 2018-10-15 2020-09-14 Consejo Superior Investigacion Gel lipidico nanoestructurado, procedimiento de preparacion y uso
CN109431963B (zh) * 2018-12-25 2021-10-26 蓓悠清(广东)健康科技有限公司 一种透明油珠悬浮精华水及其制备方法
US11633368B2 (en) 2019-09-03 2023-04-25 Milton D. Moore Enhanced moisturizing lotion compositions
CN116271179B (zh) * 2023-03-23 2024-08-20 南通大学 一种伤口敷料及其制备方法
CN116144724B (zh) * 2023-04-23 2023-07-18 养系列(山东)生物科技有限公司 一种肿瘤患者康复用复合肽、喷雾剂及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008089707A1 (en) * 2007-01-25 2008-07-31 Univerzita Pardubice Liposome of a textile auxiliary agent, method of its preparation and a preparation containing it

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2504535B1 (fr) 1981-04-28 1987-08-14 Choay Sa Disaccharides derives d'un acide uronique et d'une glucosamine et compositions pharmaceutiques les contenant pour le controle de la coagulation sanguine
GB8519416D0 (en) 1985-08-01 1985-09-04 Unilever Plc Oligosaccharides
GB8630721D0 (en) 1986-12-23 1987-02-04 Unilever Plc Cosmetic compositions
GB8806892D0 (en) 1988-03-23 1988-04-27 Unilever Plc Lactams their synthesis & use in cosmetic compositions
GB8830019D0 (en) 1988-12-22 1989-02-15 Unilever Plc Cosmetic composition
GB8913708D0 (en) 1989-06-14 1989-08-02 Unilever Plc Cosmetic composition
WO1998000092A1 (de) * 1996-07-01 1998-01-08 Hans Schwarzkopf Gmbh & Co. Kg. Verwendung von hydrogelbildnern und mittel zur behandlung keratinischer fasern
DE102004017996A1 (de) * 2004-04-10 2005-11-03 Novosom Ag Injizierbare Depots aus liposomalen Aggregaten zum Wirkstoffdelivery
CA2525468A1 (en) * 2003-05-12 2004-11-25 Novosom Ag Injectable depots consisting of liposomal aggregates for the delivery of active substances
DE10339358A1 (de) * 2003-08-27 2005-03-24 Cognis Deutschland Gmbh & Co. Kg Verwendung von Liposomen zur Ausrüstung von Fasern und Textilien
FR2870741B1 (fr) * 2004-05-25 2008-03-14 Coletica Sa Phase lamellaires hydratees ou liposomes, contenant une monoamine grasse ou un polymere cationique favorisant la penetration intercellulaire, et composition cosmetique ou pharmaceutique la contenant.
EP1842558B1 (de) * 2005-01-28 2012-06-13 Kyowa Hakko Kirin Co., Ltd. Zusammensetzung zur hemmung der expression eines zielgens
EP1972324A1 (de) * 2007-03-21 2008-09-24 Cognis IP Management GmbH Verkapselte Liposomen
WO2008144734A1 (en) * 2007-05-21 2008-11-27 Aquea Scientific Corporation Highly charged microcapsules
US20090285882A1 (en) * 2008-04-22 2009-11-19 Jochen Weiss Stabilized Liposome Compositions and Related Methods of Use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008089707A1 (en) * 2007-01-25 2008-07-31 Univerzita Pardubice Liposome of a textile auxiliary agent, method of its preparation and a preparation containing it

Also Published As

Publication number Publication date
ES2685927T3 (es) 2018-10-15
ES2373704B1 (es) 2013-01-24
ES2373704A1 (es) 2012-02-08
WO2011101153A9 (en) 2013-03-14
US9717659B2 (en) 2017-08-01
EP2536815A1 (de) 2012-12-26
US20130183358A1 (en) 2013-07-18
WO2011101153A1 (en) 2011-08-25

Similar Documents

Publication Publication Date Title
EP2536815B1 (de) Verwendung von liposomen zur behandlung von textilien
US10758490B2 (en) Nanocapsules containing microemulsions
AU2011231986B2 (en) Process of treatment of fibers and/or textile materials
ES2384060B1 (es) Cápsulas de nanopartículas lipídicas.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120906

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20160415

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

RIC1 Information provided on ipc code assigned before grant

Ipc: C11D 3/37 20060101ALI20180201BHEP

Ipc: A61Q 7/02 20060101ALI20180201BHEP

Ipc: C11D 3/22 20060101ALI20180201BHEP

Ipc: A61K 8/81 20060101ALI20180201BHEP

Ipc: D06M 13/453 20060101ALI20180201BHEP

Ipc: A61K 8/55 20060101ALI20180201BHEP

Ipc: D06M 13/292 20060101ALI20180201BHEP

Ipc: C11D 17/00 20060101ALI20180201BHEP

Ipc: A61K 8/14 20060101ALI20180201BHEP

Ipc: C11D 3/36 20060101AFI20180201BHEP

Ipc: A61Q 17/04 20060101ALI20180201BHEP

Ipc: A61K 9/127 20060101ALI20180201BHEP

Ipc: D06M 23/00 20060101ALI20180201BHEP

Ipc: C11D 3/38 20060101ALI20180201BHEP

Ipc: A61Q 19/00 20060101ALI20180201BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DELGADO GONZALEZ, RAQUEL

Inventor name: VILADOT PETIT, JOSEP-LLUIS

Inventor name: FERNANDEZ BOTELLO, ALFONSO

INTG Intention to grant announced

Effective date: 20180314

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1016882

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180715

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602011049923

Country of ref document: DE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2685927

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20181015

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20180711

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1016882

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180711

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180711

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180711

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181111

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180711

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180711

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180711

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180711

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181011

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181011

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180711

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180711

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180711

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180711

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602011049923

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180711

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180711

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180711

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180711

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180711

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180711

26N No opposition filed

Effective date: 20190412

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180711

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180711

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190218

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20190228

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190228

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180711

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20200331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181111

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180711

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180711

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20110218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180711

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230221

Year of fee payment: 13

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230528

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240228

Year of fee payment: 14

Ref country code: GB

Payment date: 20240227

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240226

Year of fee payment: 14